Skip to main content
. 2016 Sep 21;7(43):70194–70210. doi: 10.18632/oncotarget.12169

Figure 7. In vivo tumorigenic analysis of LV-miR-552-inh-infected CRC cells.

Figure 7

SCID mice were subcutaneously injected 200 μl Matrigel containing 106 LV-infected LOVO or LS174T cells, and the formation of tumor was at three weeks after the injection. (A) Images showed sizes of tumors formed from LOVO cells infected with LV-miR-552-inh (top panel) and LV-NC (bottom panel). (B) Images showed sizes of tumors formed from LS174T cells infected with LV-miR-552-inh (top panel) and LV-NC (bottom panel). (C) Relevant quantification of the sizes (diameter) of tumors derived from CRC cells expressing miR-552-inh. The result showed an ability of miR-552 inhibitor to reduced tumor sizes. Compared with LV-NC group, **p < 0.01. Data in C represented the mean ± SD from 12 animals from two independent experiments (N = 12). Bars: 1.0 cm.